HKD 5.36
(-1.83%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 386 Thousand CNY | -28.25% |
2022 | 538 Thousand CNY | -89.38% |
2021 | 5.06 Million CNY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 389.62 Thousand HKD | 22.61% |
2024 Q2 | 386.29 Thousand HKD | -0.15% |
2023 Q4 | 324.1 Thousand HKD | -92.2% |
2023 FY | 386 Thousand CNY | -28.25% |
2023 Q3 | 4.15 Million HKD | 4171.0% |
2023 Q2 | 97.26 Thousand HKD | 97.89% |
2023 Q1 | 49.15 Thousand HKD | -61.24% |
2022 FY | 538 Thousand CNY | -89.38% |
2022 Q4 | 126.79 Thousand HKD | -95.63% |
2022 Q3 | 2.9 Million HKD | 465.95% |
2022 Q2 | 513.19 Thousand HKD | 0.0% |
2021 FY | 5.06 Million CNY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Uni-Bio Science Group Limited | 484.71 Million HKD | 99.92% |
CK Life Sciences Int'l., (Holdings) Inc. | 5.32 Billion HKD | 99.993% |